твърде – -Translation – Keybot Dictionary

Spacer TTN Translation Network TTN TTN Login Deutsch Français Spacer Help
Source Languages Target Languages
Keybot 5 Results  www.kabatec.com
  Често задавани въпроси ...  
Show textShow cached sourceOpen source URL
Редките болести (РБ) може най-общо да се дефинират като патологични състояния с ниска заболеваемост и болестност. Понятието „рядкост“ е твърде относително. Въпреки, че всяко рядко заболяване се среща при много малка част от населението на една страна, ако бъдат сумирани като цяло, поради големия брой нозологични единици (над 6000), редките заболявания се превръщат в сериозен проблем за общественото здравеопазване на всяка здравна система.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine raredis.org as primary domain
Rare Diseases (RD) can generally be defined as pathological conditions with low incidence and prevalence. The term “rare” is very relative. Although each rare disease occurs in very small proportion of the population of a country, if they are aggregated as a whole, because of the large number of nosological units (over 6000), rare diseases are becoming an important public health problem of any health system.
  Критерии за реимбурсаци...  
Show textShow cached sourceOpen source URL
Статията анализира как иновативните терапии и лекарствата сираци в частност биха отговорили на критериите за реумбурсация посредством качествено прогнозиране на възможни сценарии. Анализът обобщава, че сегашната рамка за вземане на решение за реимбурсиране изглежда твърде обща, недостатъчно прозрачна и неспособна да оцени обективно иновативните здравни технологии.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine raredis.org as primary domain
A new review article explores the Bulgarian legislation on health technology assessment (HTA). It analyses how innovative therapies and orphan drugs in particular would respond to the regulators’ decision-making criteria for reimbursement through hypothetical scenario planning for orphan medicinal products. The paper concludes that the current reimbursement decision-making framework in Bulgaria seems to be generalized, not sufficiently transparent, and unable to precisely assess innovative health technologies. The article is published in the
  Синдром на Коен - Инсти...  
Show textShow cached sourceOpen source URL
Клиничната му изява при финските пациенти е твърде идентична и се състои от средно- до тежко-степенно непрогресиращо умствено изоставане, тромавост на движенията, микроцефалия, характерни лицеви белези, хипотония в детска възраст и ставна хиперподвижност, прогресивна ретино-хороидална дистрофия, късогледство, интермитентна изолирана неутропения и обикновено добро настроение.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine raredis.org as primary domain
A new disease profile is added to our database – Cohen syndrome. Cohen syndrome is one of the rare autosomal recessive disorders that are overrepresented in the Finnish population. The phenotype in Finnish patients is highly homogeneous, consisting of nonprogressive mild to severe psychomotor retardation, motor clumsiness, microcephaly, characteristic facial features, childhood hypotonia and joint laxity, progressive retinochoroidal dystrophy, myopia, intermittent isolated neutropenia, and a cheerful disposition. Characteristic facial features include high-arched or wave-shaped eyelids, a short philtrum, thick hair and low hairline. To receive a full description of this rare disease absolutely free of charge, please click here and send us a request. The profile was written by our consultant in genetics – Prof. Dr. Margarita Stefanova, MD, PhD.
  Нужда от проучвания при...  
Show textShow cached sourceOpen source URL
Но често тези случаи са недобре документирани. Освен това броят на спонтанните ремисии при рак са твърде надценени. Обещаващите индивидуални наблюдения трябва да бъдат потвърдени чрез серии случаи, за да се събере информация, която да е от полза за пациентите в бъдеще.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine raredis.org as primary domain
PubMed, the Internet portal of biomedical and life sciences literature, indexed an interesting article, entitled ”How much evidence is needed in the case of fatal diseases and when?” (Z Arztl Fortbild Qualitatssich. 2006;100(7):551-5). Author is Antes G, from the Deutsches Cochrane Zentrum, Institut fur Medizinische Biometrie und Medizinische Informatik, Albert-Ludwigs-Universitat Freiburg. Spectacular cases of healing of usually fatal diseases gain much attention and put pressure on physicians to apply treatments which have not been sufficiently approved in clinical studies. But often these cases are poorly documented. Also, the number of spontaneous remissions in cancer is greatly overestimated. Promising individual observations must be confirmed by case series in order to collect information which can help future patients. Efforts are necessary to organize well planned studies, especially on rare diseases. To access the abstract of the article, click here.
  Разработване на лекарст...  
Show textShow cached sourceOpen source URL
PubMed, порталът за биомедицинска и научна литература индексира интересна статия на тема ”Напредъкът в разработване на лекарства-сираци е твърде бавен” (Br J Clin Pharmacol. 2006 Mar;61(3):355-360). Автори са Joppi R, Bertele V и Garattini S от Института за фармакологични изследвания „Марио Негри”, Милано, Италия.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine raredis.org as primary domain
PubMed, the Internet portal of biomedical and life sciences literature, indexed an interesting article, entitled “Orphan drug development is progressing too slowly” (Br J Clin Pharmacol. 2006 Mar;61(3):355-360). Authors are Joppi R, Bertele V and Garattini S from the Mario Negri Institute for Pharmacological Research, Milan, Italy. The aims are to assess the methodological quality of OMP (Orphan Medical Products) dossiers and to discuss possible reasons for the small number of products licensed. Information about orphan drug designation and approval was obtained from the website of the European Commission-Enterprise and Industry DG and from the European Public Assessment Reports. Conclusions are that the paucity of European incentives for manufacturers and the poor documentation underpinning the applications may have limited the number of new OMP. The over 5000 rare diseases awaiting therapy are an important public health issue. To access the full abstract of the article, click here.